Randomized trial Science advances · 2026 Bifidobacterium animalis subsp. lactis V9 overcomes CYFRA 21-1-linked immunochemotherapy resistance in NSCLC via microbial metabolites. Feng C, Gao G, He Q, et al. Bifidobacterium animalis PubMed ↗
Review Frontiers in immunology · 2026 Microbiome as a prediction of immunotherapy response in lung cancer. Rojas L, Zuluaga J, Cardona AF Akkermansia muciniphilaFaecalibacterium prausnitzii PubMed ↗
Review International journal of biological sciences · 2026 Gut-Lung Microbiota Axis Shapes the Immune Microenvironment and Immunotherapeutic Response in Lung Cancer. Liu Y, Wang S, Xiang X, et al. Akkermansia muciniphila PubMed ↗
Clinical trial Nature medicine · 2026 Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial. Duttagupta S, Messaoudene M, Hunter S, et al. [Clostridium] innocuumEnterocloster citroniae PubMed ↗
Review Frontiers in immunology · 2025 Respiratory microbiome-host interaction on lung carcinogenesis, immunity, and immunotherapy. Wang P, Ge C, Jing X, et al. Escherichia coli PubMed ↗
Review Current microbiology · 2025 Non-small Cell Lung Cancer, Immunotherapy and the Influence of Gut Microbiome. Raziq MF, Manzoor H, Kayani MUR Akkermansia muciniphila PubMed ↗
Review Medicina · 2024 Insights into the Two Most Common Cancers of Primitive Gut-Derived Structures and Their Microbial Connections. Ray A, Moore TF, Naik DSL, et al. Escherichia coli PubMed ↗
Review Archives of microbiology · 2024 Butyrate's (a short-chain fatty acid) microbial synthesis, absorption, and preventive roles against colorectal and lung cancer. Karim MR, Iqbal S, Mohammad S, et al. Agathobacter rectalisFaecalibacterium prausnitzii PubMed ↗
Clinical trial International journal of radiation oncology, biology, physics · 2022 Gut Microbiome Is Associated With the Response to Chemoradiotherapy in Patients With Non-small Cell Lung Cancer. Qiu B, Xi Y, Liu F, et al. Anaerobutyricum hallii PubMed ↗
Observational Cancer causes & control · 2021 Association of oral microbiota with lung cancer risk in a low-income population in the Southeastern USA. Shi J, Yang Y, Xie H, et al. Lactococcus lactis PubMed ↗
Cancer immunology, immunotherapy · 2026 Smoking-associated modulation of gut microbiota shapes response to immune checkpoint inhibitors in non-small cell lung cancer. Chien PY, Cheng WC, Hung CC, et al. Bifidobacterium longum PubMed ↗
Microbiome · 2026 Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer. Diop K, Benlaïfaoui M, Hunter S, et al. Mediterraneibacter gnavus PubMed ↗
Gut microbes · 2026 Gut microbiota-associated nutritional-immune status predicts prognosis in postoperative NSCLC patients. Yu Q, Chen A, Yi J, et al. Anaerobutyricum hallii PubMed ↗
Journal of translational medicine · 2026 Distinct gut virome profiles are associated with response to anti-PD-1 therapy in non-small cell lung cancer. Liu Z, Liu M, Chen H, et al. Akkermansia muciniphila PubMed ↗
BMC microbiology · 2026 A real-world evidence of sputum microbiota alterations and their association with oncogenomic changes and response to targeted therapies in patients with lung cancer. Li T, Ye ZL, Yang XH, et al. Klebsiella pneumoniae PubMed ↗
Med · 2025 Gut microbiota predictive of the efficacy of consolidation immunotherapy and chemoradiotherapy toxicity in lung cancer. Wu L, Li Y, Wang W, et al. Akkermansia muciniphila PubMed ↗
Advanced science · 2025 Intravenous iRGD-Guided, RBC-Membrane Camouflaged Lactococcus Lactis Remodels Cold NSCLC and Enhances PD-1 Blockade. Chen C, Zhu J, Liu X, et al. Lactococcus lactis PubMed ↗
International journal of biological macromolecules · 2025 Akkermansia muciniphila-derived outer membrane protein Amuc_1100 promotes acetylation of RING Finger Protein 181 promoter and mediates Autophagy Related 7 ubiquitination to activate CD8+ T cells in lung adenocarcinoma. Xu Y, Qian T, Pan H, et al. Akkermansia muciniphila PubMed ↗
Journal for immunotherapy of cancer · 2025 Enhancing immunotherapy efficacy in NSCLC through the combined use of phenelzine and Akkermansia muciniphila to regulate gut microbial metabolite 5-HIAA. Sun S, Wang L, Cui K, et al. Akkermansia muciniphila PubMed ↗
Frontiers in immunology · 2025 Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression. Shimizu T, Ohkuma R, Homma M, et al. Akkermansia muciniphila PubMed ↗
Cell reports · 2025 Bifidobacterium animalis suppresses non-small cell lung cancer progression and modulates tumor immunity through indole-3-acetic acid. Song Q, Li X, Li Q, et al. Bifidobacterium animalis PubMed ↗
International journal of molecular sciences · 2025 Interconnection of Gut Microbiome and Efficacy of Immune Checkpoint Inhibitors in Inoperable Non-Small-Cell Lung Cancer. Moiseenko F, Kechin A, Koryukov M, et al. Anaerobutyricum hallii PubMed ↗
Frontiers in cellular and infection microbiology · 2025 Exploring fecal microbiota signatures associated with immune response and antibiotic impact in NSCLC: insights from metagenomic and machine learning approaches. Han W, Zhou Y, Wang Y, et al. Bacteroides caccaeSegatella copri PubMed ↗
Medicine · 2025 Bidirectional Mendelian randomization and potential mechanistic insights into the causal relationship between gut microbiota and malignant mesothelioma. Zhou Y, Zhu H, Zhao L, et al. [Clostridium] innocuum PubMed ↗
Oncoimmunology · 2025 Surrogate markers of intestinal dysfunction associated with survival in advanced cancers. Birebent R, Drubay D, Alves Costa Silva C, et al. Akkermansia muciniphila PubMed ↗
Journal of translational medicine · 2025 Prioritizing gut microbial SNPs linked to immunotherapy outcomes in NSCLC patients by integrative bioinformatics analysis. Raziq MF, Khan N, Manzoor H, et al. Lachnospira eligensParabacteroides distasonisPhocaeicola dorei PubMed ↗
Scientific reports · 2025 Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients. Grenda A, Iwan E, Kuźnar-Kamińska B, et al. Eubacterium ventriosum PubMed ↗
Frontiers in cellular and infection microbiology · 2024 Metabolic pathways from the gut metatranscriptome are associated with COPD and respiratory function in lung cancer patients. Dora D, Revisnyei P, Mihucz A, et al. Streptococcus salivarius PubMed ↗
EBioMedicine · 2024 Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivors. Liu X, Lu B, Tang H, et al. Escherichia coliFaecalibacterium prausnitzii PubMed ↗
Gut microbes · 2024 MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody. Lee PJ, Hung CM, Yang AJ, et al. Ruminococcus bromii PubMed ↗
Oncoimmunology · 2024 Faecalibaterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors. Bredon M, Danne C, Pham HP, et al. Faecalibacterium prausnitzii PubMed ↗
International journal of molecular sciences · 2024 Dynamic Changes of the Gut Microbiota and Its Functional Metagenomic Potential during the Development of Non-Small Cell Lung Cancer. Feng C, Li N, Gao G, et al. Akkermansia muciniphila PubMed ↗
Archives of Iranian medicine · 2024 Gut-Lung Microbiota Characterization in Patients with Non-Small Cell Lung Carcinoma and COVID-19 Coinfection. Vakili B, Shoaei P, Shahzamani K, et al. Akkermansia muciniphila PubMed ↗
Frontiers in cellular and infection microbiology · 2023 Structure of gut microbiota and characteristics of fecal metabolites in patients with lung cancer. Lu X, Xiong L, Zheng X, et al. Mediterraneibacter gnavus PubMed ↗
Oncoimmunology · 2023 Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status. Dora D, Ligeti B, Kovacs T, et al. Alistipes finegoldiiAlistipes shahiiBifidobacterium breveStreptococcus salivarius PubMed ↗
Scientific reports · 2023 Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit. Haberman Y, Kamer I, Amir A, et al. Akkermansia muciniphilaAlistipes onderdonkiiFaecalibacterium prausnitzii PubMed ↗
International journal of environmental research and public health · 2022 Impact of Gut Dysbiosis on the Risk of Non-Small-Cell Lung Cancer. Wei YF, Huang MS, Huang CH, et al. Bacteroides caccae PubMed ↗
Microbiology spectrum · 2022 MADET: a Manually Curated Knowledge Base for Microbiomic Effects on Efficacy and Toxicity of Anticancer Treatments. Zhang J, Chen X, Zou J, et al. Akkermansia muciniphila PubMed ↗
Cancer medicine · 2022 Bifidobacterium breve predicts the efficacy of anti-PD-1 immunotherapy combined with chemotherapy in Chinese NSCLC patients. Zhao H, Li D, Liu J, et al. Bifidobacterium breve PubMed ↗
Disease markers · 2022 Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy. Wu C, Wang X, Shang H, et al. Bifidobacterium longum PubMed ↗